Despite Setbacks, pCR Still Acceptable for Breast Cancer Approvals

Despite Setbacks, pCR Still Acceptable for Breast Cancer Approvals

Pathologic complete response (pCR) may still have a role in accelerated neoadjuvant approvals for select patients with early stage breast cancer, despite the fact that it remains an unproven surrogate endpoint, according to Gunter von Minckwitz, MD

(Visited 2 times, 1 visits today)
7
Like
Save

Comments

Comments are disabled for this post.